These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 1457929)

  • 1. Low calcium peritoneal dialysis solution. Effects on calcium metabolism and bone disease in CAPD patients.
    Carozzi S; Nasini MG; Schelotto C; Caviglia PM; Santoni O; Pietrucci A
    ASAIO J; 1992; 38(3):M593-5. PubMed ID: 1457929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Ca2+ dialysate. Effects on bone metabolism in the course of paired filtration dialysis.
    Carozzi S; Nasini MG; Pietrucci A; Costa M; Mantero R
    ASAIO J; 1994; 40(3):M683-5. PubMed ID: 8555601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low- and high-turnover bone disease in continuous ambulatory peritoneal dialysis: effects of low-Ca2+ peritoneal dialysis solution.
    Carozzi S; Nasini MG; Santoni O; Pietrucci A
    Perit Dial Int; 1993; 13 Suppl 2():S473-5. PubMed ID: 8399644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
    Weinreich T; Ritz E; Passlick-Deetjen J
    Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversibility of parathyroid gland suppression in CAPD patients with low i-PTH levels.
    Montenegro J; Saracho R; González O; Moina I; Martínez I
    Clin Nephrol; 1997 Dec; 48(6):359-63. PubMed ID: 9438094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder.
    Cheng IK; Lu HB; Chan CY; Cheng SW; Robinson JD; Tam SC; Lo WK; Cheung WC
    Clin Nephrol; 1993 Aug; 40(2):100-5. PubMed ID: 8222365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
    Bro S; Brandi L; Olgaard K
    Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial comparing 2.5 mEq/L calcium dialysate and calcitriol to 3.5 mEq/L calcium dialysate in patients on peritoneal dialysis.
    Banalagay E; Bernardini J; Holley J; Chen T; Piraino B
    Adv Perit Dial; 1993; 9():280-3. PubMed ID: 8105943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAPD with low calcium dialysate and calcium carbonate: results of a 24-week study.
    Honkanen E; Kala AR; Grönhagen-Riska C; Ikäheimo R
    Adv Perit Dial; 1992; 8():356-61. PubMed ID: 1361822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The impact of low calcium dialysate (1.25 mmol/l; LCD) on bone metabolism in CAPD patients].
    Terawaki H; Kasai K; Kawaguchi Y; Kobayashi H; Hirano K; Ohtsuka Y; Hosoya T
    Nihon Jinzo Gakkai Shi; 1998 May; 40(4):252-7. PubMed ID: 9654908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose oral calcitriol and zero calcium peritoneal solutions in CAPD patients with refractory secondary hyperparathyroidism.
    Malberti F; Scanziani R; Corradi B; Dozio B; Bonforte G; Imbasciati E; Surian M
    Nephrol Dial Transplant; 1994; 9(12):1813-5. PubMed ID: 7708273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.
    Brandi L; Nielsen PK; Bro S; Daugaard H; Olgaard K
    J Intern Med; 1998 Aug; 244(2):121-31. PubMed ID: 10095798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
    Yaginuma T; Yamamoto H
    Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD.
    Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK
    Clin Nephrol; 1989 Aug; 32(2):96-100. PubMed ID: 2766587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium.
    Spasovski G; Gelev S; Masin-Spasovska J; Selim G; Sikole A; Vanholder R
    Bone; 2007 Oct; 41(4):698-703. PubMed ID: 17643363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study.
    Sánchez C; López-Barea F; Sánchez-Cabezudo J; Bajo A; Mate A; Martínez E; Selgas R;
    Nephrol Dial Transplant; 2004 Jun; 19(6):1587-93. PubMed ID: 15069173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low calcium (1.25 mmol/L) dialysate can normalize relative hypoparathyroidism in CAPD patients with low bone turnover.
    Shigematsu T; Kawaguchi Y; Kubo H; Nakayama M; Kato N; Yamamoto H; Osaka N; Hayakawa H; Ogawa A; Sakai O
    Adv Perit Dial; 1996; 12():250-6. PubMed ID: 8865914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
    Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
    J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.